기자가 쓴 기사 더보기

[편집자 주 - 너무 어린 아이들이 강력한 향정신성 의약품에 쉽게 노출되어 있다는 기사입니다]
At 18 months, Kyle Warren started taking a daily antipsychotic drug on the orders of a pediatrician to quell the boy's severe tempter tantrums.
Thus began a troubled toddler's journey from one doctor to another, from one diagnosis to another, involving even more drugs. Autism, bipolar disorder, hyperactivity, insomnia, oppositional defiant disorder. The boy's daily pill regimen multiplied: the antipsychotic Risperdal [리스페달], the antidepressant Prozac [프로작], two sleeping medicines and one for attention-deficit disorder. All by the time he was 3.
He was sedated, drooling and overweight from the side effects of the antipsychotic medicine. Although his mother, Brandy Warren, had been at her "wit's end" when she resorted to the drug treatment, she began to worry about Kyle's altered personality.
"All I had was a medicated little boy," Ms. Warren said. "I didn't have my son. It's like, you'd look into his eyes, and you would just see just blankness."
Today, Kyle, 6, is in his forth week of first grade, scoring high marks on his first tests. He is rambunctious and much thinner. Weaned off the drugs through a program affiliated with Tulane University in New Orleans [U.S.A.] that is aimed at helping low-income families whose children have mental health problems, Kyle now laughs easily and teases his family.
Ms. Warren and Kyle's new doctors point to his remarkable progress - and a more common diagnosis for children of attention-deficit hyperactivity disorder - as proof that he should have never been prescribed such powerful drugs in the first place.
| 인기기사 | 더보기 + |
| 1 | 대전선병원 김기덕 센터장 “몇백억 유산균보다 중요한 건 장내 생태계” |
| 2 | CSO 세무조사, 가공경비·현금흐름 꼬리 밟히면 원청 제약사도 타격 |
| 3 | 네이처셀 아메리카, ‘바스코스템’ FDA pre-IND 미팅 10월 23일 확정 |
| 4 | MSD서 키트루다 병용 꿰뚫은 한진환 CTO…리가켐바이오 ADC 전략 ‘면역·독성 설계’ |
| 5 | "뇌 전이 효능도 확보" 보로노이 ‘VRN110755’ 3세대 EGFR 내성 환자 6명 모두 종양 감소 |
| 6 | 에스티큐브 유승한 미국대표 “EGFR 변이 폐암 2상 효능 첫 공개…ORR 37.5%·오시머티닙 병용 추진” |
| 7 | 메지온, ADPKD 치료제 글로벌 임상 가속..미국 현지법인 설립 |
| 8 | 상장 제약·바이오사 상반기 평균 연구개발비 코스피 386억원, 코스닥 67억원 |
| 9 | [BMK2026]삼성바이오로직스, ADC 상업화 앞당긴다…제형·공정 최적화 전략 제시 |
| 10 | 상장 제약·바이오사 상반기 평균 해외매출 코스피 1771억원, 코스닥 259억원 |
| 인터뷰 | 더보기 + |
| PEOPLE | 더보기 + |
| 컬쳐/클래시그널 | 더보기 + |

[편집자 주 - 너무 어린 아이들이 강력한 향정신성 의약품에 쉽게 노출되어 있다는 기사입니다]
At 18 months, Kyle Warren started taking a daily antipsychotic drug on the orders of a pediatrician to quell the boy's severe tempter tantrums.
Thus began a troubled toddler's journey from one doctor to another, from one diagnosis to another, involving even more drugs. Autism, bipolar disorder, hyperactivity, insomnia, oppositional defiant disorder. The boy's daily pill regimen multiplied: the antipsychotic Risperdal [리스페달], the antidepressant Prozac [프로작], two sleeping medicines and one for attention-deficit disorder. All by the time he was 3.
He was sedated, drooling and overweight from the side effects of the antipsychotic medicine. Although his mother, Brandy Warren, had been at her "wit's end" when she resorted to the drug treatment, she began to worry about Kyle's altered personality.
"All I had was a medicated little boy," Ms. Warren said. "I didn't have my son. It's like, you'd look into his eyes, and you would just see just blankness."
Today, Kyle, 6, is in his forth week of first grade, scoring high marks on his first tests. He is rambunctious and much thinner. Weaned off the drugs through a program affiliated with Tulane University in New Orleans [U.S.A.] that is aimed at helping low-income families whose children have mental health problems, Kyle now laughs easily and teases his family.
Ms. Warren and Kyle's new doctors point to his remarkable progress - and a more common diagnosis for children of attention-deficit hyperactivity disorder - as proof that he should have never been prescribed such powerful drugs in the first place.